Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Jan;15(1):247-54.
doi: 10.1093/ntr/nts121. Epub 2012 May 15.

Safety of varenicline among smokers enrolled in the lung HIV study

Amy K Ferketich  1 , Philip Diaz, Kristine K Browning, Bo Lu, Susan L Koletar, Nancy R Reynolds, Mary Ellen Wewers
Affiliations
Clinical Trial

Safety of varenicline among smokers enrolled in the lung HIV study

Amy K Ferketich et al. Nicotine Tob Res. 2013 Jan.

Abstract

Introduction: The prevalence of smoking is high among the human immunodeficiency virus (HIV)-infected population, yet there are few studies of tobacco dependence treatment in this population. This paper reports the safety of varenicline versus nicotine replacement therapy (NRT) and describes preliminary results about the effectiveness of varenicline versus NRT in HIV-infected smokers.

Methods: Participants completed 12 weeks of telephone counseling and either varenicline or NRT. Varenicline was encouraged as the preferred intervention; NRT was used for those unable/unwilling to take varenicline. Adverse events (AEs), related to pharmacotherapy, were monitored. Biochemically confirmed abstinence at 3 months was examined. Inverse probability of treatment weighted logistic regression models was fit to compare participants on varenicline to those on NRT.

Results: Among participants on varenicline (n = 118), the most common AEs were nausea, sleep problems, and mood disturbances. One person reported suicidal ideation; there were no cardiovascular complications. There were no differences in the varenicline AE profile between participants on combination antiretroviral therapy (ART) and those not on ART. The percentages of confirmed abstainers were 11.8% in the NRT group and 25.6% in the varenicline group. The odds of being abstinent were 2.54 times as great in the varenicline group compared with the NRT group in the propensity weighted model (95% CI 1.43-4.49).

Conclusions: In this preliminary study, the safety profile of varenicline among HIV-infected smokers resembles findings among smokers without HIV. In addition, varenicline may be more effective at promoting abstinence in this population. Future randomized clinical trials are warranted.

PubMed Disclaimer

References

    1. Barnes PM, Ward BW, Freeman G, Schiller JS. Early release of selected estimates based on data from the January–September 2010 National Health Interview Survey. National Center for Health Statistics; 2011. Retrieved from http://www.cdc.gov/nchs/nhis.htm.
    1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:561–571. - PubMed
    1. Benard A, Mercie P, Alioum A, Bonnet F, Lazaro E, Dupon M, et al. Bacterial pneumonia among HIV-infected patients: Decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000–2007. PLoS One. 2010;5:e8896. doi:10.1371/journal.pone.0008896. - PMC - PubMed
    1. Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine & Tobacco Research. 2005;7:511–522. doi:10.1080/14622200500186064. - PubMed
    1. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2011;(2):CD006103. doi:10.1002/14651858.CD006103.pub5. - PubMed

Publication types